で公開中です！詳しく見る

Dare Bioscience

DARE

時価総額 $1425万

0.7246 USD

-0.0154

2.08%

終値時点更新済み 10月16日 16:00 EDT

1日

-2.08%

5日間

-5.9%

1か月

-0.12%

3か月

-62.65%

6か月

-73.36%

年初来

-62.84%

1年

-65.82%

5年間

-96.25%

10年間

-99.13%

概要： Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

従業員数： 24

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic priorities

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities

ニュートラル

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

ニュートラル

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

ニュートラル

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

View the video webcast here

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

ニュートラル

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

ニュートラル

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Video webcast now available here

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

ニュートラル

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript

ニュートラル

Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**

Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

ニュートラル

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

ニュートラル

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています